NEW YORK (GenomeWeb News) – Quest announced today a definitive agreement to sell its HemoCue business to Danaher's Radiometer Medical for about $300 million.

Separately, Fitch Ratings affirmed Quest Diagnostics' Issuer Default Rating at BBB+ after the close of the market on Friday.

Based in Cypress, Calif., HemoCue develops hemoglobin, glucose, and other point-of-care testing systems.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.